

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE ATTORNEY DOCKET NO. 065678-0108

Applicant: Naoshi FUKUSHIMA et al.

Title: AGONIST ANTIBODIES

Appl. No.: 10/645,085

Filing Date: 10/07/2002

Examiner: Unassigned

Art Unit: 1653

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

Atty. Dkt. No. 065678-0108

Appl. No. 10/645,085

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding European application. A copy of the European Search Report is attached setting forth the portion of each document considered relevant by the examiner. The absence of a translation does not relieve the PTO from its duty to consider any submitted document (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone: Facsimile:

(202) 672-5569

(202) 672-5399

Registration No. 35,264

Stephen B. Maebius

Attorney for Applicant

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for fo	orm 1449B/I	то		C	complete if Known	
	INFORMATION	DISCLOS	SURE 1	PE	Application Number	10/645,085	
	STATEMENT E	BY APPLIC	(DAX)		Filing Date	10/07/2002	
			/	OE	First Named Inventor	Naoshi FUKUSHIMA et al.	
			AAR	0 J 5000 d	Group Art Unit	1653	
	(use as many she	ets as ned	essaly	1	Examiner Name	Unassigned	
Sheet	1	of	Pro.	***	Attorney Docket Number	065678-0108	
	<u> </u>			TRADE			

U.S. PATENT DOCUMENTS						
	U.S. Patent	Document		Date of Publication of	Pages, Columns, Lines, Where Relevant	
Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
				·		
	Cite No.1	Cite	No. ¹ Number Code ² (if	Cite No.1	Cite No. 1 Number Kind Code ² (if known) Name of Patentee or Applicant of Cited Document MM-DD-YYYY	

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	F Office	oreign Patent [Document Kind Co	ode ⁵	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1	EP	0 721 015		A1	CHUGAI SEIYAKU KK	07/10/1996		
	B2	wo	97/32601		A1_	CHUGAI SEIYAKU KK	09/12/1997		
									ļ
		ļ .							

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ ⁶
	В3	LINDBERG et al., "Molecular Cloning of Integrin-Associated Protein: An Immunoglobulin Family Member with Multiple Membrane-Spanning Domains Implicated in α _ν β ₃ -Dependent Ligand Binding," The Journal of Cell Biology, Vol. 123, No. 2, The Rockefeller University Press, October 1993, pp. 485-496.	
	B4	MATEO et al., "Induction of Apoptosis in B-Cells From Chronic Lymphocytic Leukemia (B-CLLs) by CD47," FASEB Journal, Vol. 12, No. 5, March 20, 1998, pg. A1082.	
	B5	FUKUSHIMA et al., "Apoptosis of Bone Marrow Cells Via Integrin Associated Protein by the Novel Monoclonal Antibody," Blood, Vol. 94, No. 10, November 15, 1999, pg. 479A	

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.